- Home
- NVO
NVO
Novo Nordisk A/S
as 05-30-2025 4:00pm EST
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
| Founded: | 1923 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 278.0B | IPO Year: | N/A |
| Target Price: | $128.00 | AVG Volume (30 days): | 11.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 3.40 | EPS Growth: | 17.93 |
| 52 Week Low/High: | $57.00 - $148.15 | Next Earning Date: | 05-07-2025 |
| Revenue: | $43,922,211,349 | Revenue Growth: | 24.11% |
| Revenue Growth (this year): | 18.59% | Revenue Growth (next year): | 15.61% |
Latest Novo Nordisk A/S News
NVO Breaking Stock News: Dive into NVO Ticker-Specific Updates for Smart Investing
Motley Fool
18 hours ago
2 Top Stocks to Buy With Less Than $100
Motley Fool
19 hours ago
2 Beaten-Down Stocks to Buy on the Dip
Quartz
21 hours ago
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Insider Monkey
a day ago
Was Jim Cramer Right About Eli Lilly and Company (LLY)?
Barrons.com
a day ago
Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.
Investor's Business Daily
2 days ago
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
The Wall Street Journal
2 days ago
How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created
Healthcare Dive
3 days ago
GLP-1 prescriptions for weight loss are shooting up, despite obstacles
Compare NVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVO Novo Nordisk A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.